Active Surveillance for Prostate Cancer: Monitoring Low-Risk Cancer
- What is active surveillance?
- Who qualifies for active surveillance?
- Active surveillance vs. watchful waiting
- Monitoring protocol – PSA, DRE, MRI, repeat biopsy
- When to stop and treat – triggers for intervention
- Benefits – avoids overtreatment, preserves quality of life
- Risks – progression, anxiety, need for follow-up
- Success rates – 50-70% avoid treatment at 10 years
- Interactive FAQ – 9 questions about active surveillance
What is active surveillance?
Active surveillance is a management strategy for men with low-risk prostate cancer. Instead of immediate treatment (surgery or radiation), the cancer is closely monitored with regular PSA tests, digital rectal exams (DRE), MRIs, and repeat biopsies. Treatment is only given if the cancer shows signs of progression.
Active surveillance avoids or delays the side effects of treatment (erectile dysfunction, urinary incontinence) without compromising the chance of cure.
Who qualifies for active surveillance?
Not all men with prostate cancer are candidates for active surveillance. Ideal candidates have low-risk or favorable intermediate-risk cancer:
Low-risk (all of the following):
- Clinical stage T1-T2a
- Gleason score 6 (3+3)
- PSA <10 ng/mL
- Fewer than 3 positive biopsy cores
- Less than 50% cancer in any core
Favorable intermediate-risk (select patients):
- Gleason 3+4=7 (Grade Group 2)
- PSA <10 ng/mL
- Low volume of pattern 4 (minimal)
- Patient preference after discussion
Not candidates:
- Gleason 4+3=7 or higher
- PSA >20 ng/mL
- Clinical stage T3 or higher
- Life expectancy <10 years (consider watchful waiting instead)
Active surveillance vs. watchful waiting
These terms are often confused but have different meanings:
- Active surveillance: For healthy men with life expectancy >10 years. Regular monitoring (PSA, MRI, biopsies) with intent to cure if cancer progresses.
- Watchful waiting: For elderly or frail men with life expectancy <10 years. No routine monitoring. Treat only if symptoms develop (pain, urinary obstruction). No intent to cure.
| Feature | Active Surveillance | Watchful Waiting |
|---|---|---|
| Patient population | Healthy, >10 years life expectancy | Frail/elderly, <10 years life expectancy |
| Monitoring | Regular PSA, MRI, repeat biopsies | No routine monitoring |
| Goal | Delayed curative treatment | Symptom management only |
| Treatment trigger | Cancer progression (Gleason, stage) | Symptoms (pain, obstruction) |
Monitoring protocol – PSA, DRE, MRI, repeat biopsy
The active surveillance protocol varies by institution, but typical schedules include:
PSA testing:
- Every 3-6 months for the first 2 years
- Every 6-12 months thereafter
Digital Rectal Exam (DRE):
- Every 6-12 months
Multiparametric MRI (mpMRI):
- Baseline MRI at enrollment
- Repeat MRI every 1-3 years
- PI-RADS 4-5 lesions trigger repeat biopsy
Repeat prostate biopsy:
- Within 12-18 months of initial biopsy
- Then every 2-3 years until age 80 or life expectancy <10 years
- MRI-targeted biopsy if suspicious lesion appears
When to stop and treat – triggers for intervention
Treatment (surgery or radiation) is recommended if any of the following occur:
- Gleason score upgrade: To 3+4=7 (Grade Group 2) or higher on repeat biopsy
- Increase in cancer volume: More cores positive or higher percentage of cancer
- Clinical stage progression: Palpable nodule (T2c or higher) on DRE
- Rapid PSA rise: PSA doubling time <3 years (controversial, not sole trigger)
- Patient anxiety: Some men choose treatment despite stable cancer
Benefits – avoids overtreatment, preserves quality of life
Active surveillance offers significant benefits:
- Avoids overtreatment: 50-70% of men never need treatment
- Preserves erectile function: Avoids surgery-related ED (occurs in 20-50% after treatment)
- Preserves urinary continence: Avoids surgery-related incontinence (5-10%)
- Avoids radiation side effects: Fatigue, urinary/bowel symptoms
- Maintains quality of life: No impact on daily activities
- Cost-effective: Avoids expensive treatments
Risks – progression, anxiety, need for follow-up
Active surveillance has potential downsides:
- Risk of progression: 20-30% of men will progress to higher Gleason score within 10 years and need treatment
- Anxiety: Some men worry about untreated cancer (psychological burden)
- Need for repeat biopsies: Invasive procedure with infection risk (1-5%)
- Loss to follow-up: Some men miss appointments and are not monitored adequately
- Rare risk of metastasis: Extremely low (<1% at 10 years) for properly selected patients
Success rates – 50-70% avoid treatment at 10 years
Long-term studies show excellent outcomes with active surveillance:
- 10-year treatment-free rate: 50-70% (30-50% eventually need treatment)
- 10-year prostate cancer-specific survival: >99%
- 10-year metastasis rate: <1%
- 15-year metastasis rate: 1-2%
When treatment is needed, it is still curative:
- Men who progress to Gleason 7 on surveillance can still be cured with surgery or radiation
- Delaying treatment does not worsen outcomes (cancer is still localized)
Interactive FAQ – Active surveillance for prostate cancer
Yes – metastasis risk <1% at 15 years. Active surveillance is the standard of care for Gleason 6.
Typically at 12-18 months, then every 2-3 years. MRI may reduce the need for frequent biopsies.
You will be offered curative treatment (surgery or radiation). Delaying treatment does not worsen outcomes.
Select patients with favorable intermediate-risk (low volume of pattern 4) may qualify. Discuss with your urologist.
Some men experience anxiety about untreated cancer. Support groups and counselling can help. Most men adjust well.
Active surveillance: regular monitoring, intent to cure. Watchful waiting: no monitoring, treat symptoms only (for frail elderly).
PSA alone is not a trigger. Treatment is based on biopsy results (Gleason upgrade) or MRI findings.
30-50% at 10 years. 50-70% avoid treatment entirely.
Yes – you can choose treatment at any time. Discuss with your urologist.
Disclaimer: This information is for educational purposes. Active surveillance requires strict adherence to monitoring protocols. Discuss with a urologist at Vivekananda Hospital to determine if you are a candidate.